Locally Advanced or Metastatic Solid Tumors
Locally Advanced or Metastatic Solid Tumors are cancers that have spread from their original site to nearby tissues or other parts of the body, often requiring complex treatment strategies.
HER3-DXd for Advanced Solid Tumors
We are studying a new treatment for patients with locally advanced or metastatic solid tumors to see if it is effective and safe. This trial will help us understand how well it works and its relationship with tumor characteristics.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have locally advanced or metastatic cancer that cannot be treated with surgery or radiation?
- Are you currently pregnant or breastfeeding?
- Are you taking any medications that suppress your immune system, like prednisone or other steroids?
- Do you have any significant heart problems or uncontrolled infections?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Patritumab Deruxtecan
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Brussel
Medical Oncology
Ganshoren, Belgium
UZ Leuven
Medical Oncology
Heverlee, Belgium
Universitair Ziekenhuis Gent
Medical Oncology
Ledeberg, Belgium
Sponsor: Daiichi Sankyo Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.